Inventor · disambiguated record
Jean-Francois Pujol
Also filed as: PUJOL JEAN-FRANCOIS · PUJOL JEAN-FRANÇOIS
6 granted patents·9 pending applications·2 citations·filing 2005–2024
69Inventor score
Top patents by PatentIndex Score
15 records- 0169US8771953B2Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platformWEISSMANN DINAH·Filed 2009·Granted Jul 8, 2014·1 cites·29 claims
- 0267US2025270645A1Algorithm and an in vitro method based on rna editing to select particular effect induced by active compoundsALCEDIAG·Filed 2024·Application pending·0 cites
- 0364US10851420B2Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effectsALCEDIAG·Filed 2019·Granted Dec 1, 2020·0 cites·16 claims
- 0461US7354918B2Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol and applications thereofBIOCORTECH·Filed 2006·Granted Apr 8, 2008·1 cites·20 claims
- 0561US2014356875A1Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platformALCEDIAG·Filed 2014·Application pending·0 cites
- 0655US10323283B2Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effectsALCEDIAG·Filed 2017·Granted Jun 18, 2019·0 cites·15 claims
- 0754US2017253926A1Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platformALCEDIAG·Filed 2017·Application pending·0 cites
- 0852US2013178493A1Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disordersBIOCORTECH·Filed 2012·Application pending·0 cites
- 0951US11873531B2Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effectsALCEDIAG·Filed 2020·Granted Jan 16, 2024·0 cites·15 claims
- 1051US2007155769A1Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disordersBIOCORTECH·Filed 2005·Application pending·0 cites
- 1143US2019249251A1Algorithm and an in vitro method based on rna editing to select particular effect induced by active compoundsALCEDIAG·Filed 2017·Application pending·0 cites
- 1241US2011201636A1Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disordersBIOCORTECH·Filed 2011·Application pending·0 cites
- 1340US2015056622A1Editing profiling of pde8a pre -mrna: use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effectsWEISSMANN DINAH·Filed 2013·Application pending·0 cites
- 1437US12084719B2RNA editing as biomarkers for mood disorders testALCEDIAG·Filed 2017·Granted Sep 10, 2024·0 cites·8 claims
- 1536US2009258883A11H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide CompoundsSERVIER LAB·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jean-Francois Pujol files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →